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Abstract
Background: Aristaless related homeobox (ARX) is a paired-type homeobox gene. ARX function is frequently
affected by naturally occurring mutations. Nonsense mutations, polyalanine tract expansions and missense
mutations in ARX cause a range of intellectual disability and epilepsy phenotypes with or without additional
features including hand dystonia, lissencephaly, autism or dysarthria. Severe malformation phenotypes, such as X-
linked lissencephaly with ambiguous genitalia (XLAG), are frequently observed in individuals with protein
truncating or missense mutations clustered in the highly conserved paired-type homeodomain.
Results: We have identified two novel point mutations in the R379 residue of the ARX homeodomain; c.1135C>A,
p.R379S in a patient with infantile spasms and intellectual disability and c.1136G>T, p.R379L in a patient with XLAG.
We investigated these and other missense mutations (R332P, R332H, R332C, T333N: associated with XLAG and
Proud syndrome) predicted to affect the nuclear localisation sequences (NLS) flanking either end of the ARX
homeodomain. The NLS regions are required for correct nuclear import facilitated by Importin 13 (IPO13). We
demonstrate that missense mutations in either the N- or C-terminal NLS regions of the homeodomain cause
significant disruption to nuclear localisation of the ARX protein in vitro. Surprisingly, none of these mutations
abolished the binding of ARX to IPO13. This was confirmed by co-immunoprecipitation and immmuno
fluorescence studies. Instead, tagged and endogenous IPO13 remained bound to the mutant ARX proteins, even in
the RanGTP rich nuclear environment. We also identify the microtubule protein TUBA1A as a novel interacting
protein for ARX and show cells expressing mutant ARX protein accumulate in mitosis, indicating normal cell
division may be disrupted.
Conclusions: We show that the most likely, common pathogenic mechanism of the missense mutations in NLS
regions of the ARX homeodomain is inadequate accumulation and distribution of the ARX transcription factor
within the nucleus due to sequestration of ARX with IPO13.
Background
The genes on the X-chromosome contribute signifi-
cantly to genetic aetiology of intellectual disability [1].
The Aristaless related homeobox gene (ARX) [GenBank:
NM_139058.2] is one of the more frequent contributors
[1]. ARX belongs to a subset of Aristaless-related
Paired-class (Prd-class) homeodomain proteins [2] and
contains multiple domains, including the aristaless
domain, homeodomain, the octapeptide and 4 polyala-
nine tracts [3]. ARX mutations cause intellectual
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disability with or without additional features including
epilepsy, infantile spasms, dystonia, lissencephaly, autism
and dysarthia [3-5]. To date, over 90 families and indivi-
dual cases with 40 different types of mutations have
been reported. These include missense mutations, pro-
tein truncations but most frequently, polyalanine tract
expansions [6-19].
When Arx was first ablated in mouse [5], the pheno-
type recapitulated many clinical aspects of X-linked lis-
sencephaly with ambiguous genitalia [XLAG; MIM
300215] [20,21]. Subsequently, this led to the identifica-
tion of ARX mutations in patients with XLAG [5]. Lis-
sencephaly is one of a heterogenous group of disorders
arising from aberrant neuronal migration. The charac-
teristic ‘smooth brain’, due to a paucity of normal gyri
and sulci, is due to either the arrest of neuronal migra-
tion (classical) or an over-migration of neurons (cobble-
stone). Mutations in the X-linked gene DCX (MIM
300121) [22] and four autosomal genes: LIS1 (MIM
601545) [23], RELN (MIM 600514) [24], TUBA1A
(MIM 602529) [25,26] and VLDLR (MIM 192977) [27]
have been associated with distinct lissencephaly syn-
dromes. However, mutations in ARX are the only identi-
fied genetic cause underlying the distinct syndrome of
XLAG. This syndrome differs from the other forms of
lissencephaly, displaying a thickened cortex with poster-
ior to anterior gradient of gyral malformation, agenesis
of the corpus callosum and ambiguous genitalia [28].
There are currently 31 families reported with XLAG
phenotypes, with and without additional features, due to
27 different mutations in ARX. The majority of these
families are predicted to arise from protein truncation
and the loss-of-function of the mature ARX protein
[5,7,9,12,28-31]. In the remaining families with XLAG,
single nucleotide substitutions clustered in the homeo-
domain or, in one case, just prior to the aristaless
domain, are predicted to give rise to amino acid substi-
tutions in the mature protein. Several of these single
nucleotide substitutions occur in residues of nuclear
localization sequences (NLS) that flank both ends of the
ARX homeodomain. In the N-terminal NLS (NLS2)
there are four naturally occurring point mutations -
R332P, R332H and R332C which cause XLAG and a
residue adjacent to this arginine, T333N, which causes
Proud syndrome (agenesis of the corpus callosum with
ambiguous genitalia) [ACC/AG; MIM 30004]. We have
recently identified novel point mutations in a single resi-
due of the NLS3 region flanking the C-terminal portion
of the homeodomain, R379. In one case, a substitution
of R379 with lysine (L) has been identified in a patient
presenting a phenotype of XLAG (D Coman, unpub-
lished data). In contrast, a second change in the same
residue resulting in the substitution of R379 with serine
(S) was identified in a proband and his female relatives
[32]. Interestingly, the phenotype includes infantile
spasms and severe mental retardation without obvious
brain malformation.
The basic residues of ARX NLS2 and NLS3 are
important for the correct localization of ARX in the
nucleus through interaction with Importin 13 (IPO13)
[33]. IPO13 is a member of the importin-b superfamily
involved in nuclear import and export of a variety of
proteins [34,35]. In addition to IPO13, a recent study
suggests that multiple importins are utlized to import
murine Arx into the nucleus, including importin b1
[36]. Regardless of the importin utilized, the driving
force for nuclear protein import is provided by RanGTP
and its interaction with the importin-cargo complex
[37]. We show that missense mutations of NLS2 and
NLS3 cause significant disruption to the nuclear locali-
zation of ARX in vitro. However, these mutations do
not abolish the binding of ARX to IPO13. Interestingly,
the binding of mutant ARX protein to endogenous
IPO13 is indistinguishable from the binding to N-term-
inally truncated IPO13 lacking the RanGTPase binding
domain. Hence, the ability of the mutant ARX-IPO13
complex to uncouple in the RanGTP rich nuclear envir-
onment appears to be compromised. As part of our
investigation into the pathogenic mechanism underlying
these mutations we identify TUBA1A, a component of
the cytoskeleton important in mitosis, as a novel protein
partner for ARX and examine the impact of sequestra-
tion of mutant ARX cargo with IPO13 on mitosis and
cell division.
Materials and methods
Subjects and families
The relevant research ethics committees and institu-
tional review boards of collaborating institutions
approved this study. Clinical information and DNA sam-
ples were collected with informed consent.
Cloning of mutant full-length ARX constructs
The cloning of the full-length human ARX cDNA con-
struct in pCMV-Myc vectors (ARX-Wt; 1-562 aa) and
the V5-IPO13 (aa 217-963; minus the RanGTPase bind-
ing site) have been described previously [33]. Single
nucleotide substitutions were introduced into the
pCMV-Myc-ARX-Wt full-length construct via site direc-
ted mutagenesis (Stratagene) following the manufac-
turer’s instructions. The mutations included c.995G>C
leading to p.R332P (R332P) in the NLS2 region,
c.998C>A leading to p.T333N (T333N) close to NLS2,
c.1136G>T leading to p.R3479L (R379L) and c.1135C>A
leading to p.R379S (R379S) in the NLS3 region. A dou-
ble mutant construct was engineered with a mutation in
each the NLS2 (c.995G>C) and NLS3 (c.1136G>T)
regions in the same cDNA construct (R332P-R379L). In
addition, a construct containing a c.1058C>T change
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leading to p.P353L (P353L) was engineered to provide
an ARX mutation located within the homeodomain but
outside of the NLS regions. All clone preparations were
verified by sequencing of the entire coding region.
Cell culture and transient transfection
HEK293T cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% (v/v) fetal calf
serum. All cells were cultured in the presence of 100 U/
ml sodium penicillin and 100 μg/ml of streptomycin sul-
phate in 5% CO2 at 37°C. Cells plated at 4 × 10
5 per
well in a six- well plate the day before transfection in
media lacking antibiotics. Routinely, cells were trans-
fected with a total of 1 μg of plasmid DNA using Lipo-
fectamine 2000 (Invitrogen, CA, USA) following the
manufacturer’s instructions.
Antibodies
The following antibodies were used for immunofluores-
cence and/or western immunoblot analysis: mouse anti-
ARX antibody (2 μg/ml final); goat anti-IPO13 (1:500)
(Imgenex, CA, USA); rabbit-anti-alpha-tubulin (1:1500)
(Rockland, PA, USA); rabbit anti-V5 antibody (1:5000)
(Bethyl Laboratories, Tx, USA). The secondary antibo-
dies were either fluorescent labelled; goat anti-mouse-
IgG conjugated to CY3 (1:1000) (Jackson Laboratories,
Maine, USA); goat anti-mouse-IgG conjugated to FITC
(1:1000) (Dako, Glostrup, Sweden); goat anti-rabbit-IgG
Alexa Fluor 488 (1:800) (Invitrogen); donkey anti-goat-
IgG Alexa Fluor 555 (1:1000) (Invitrogen) or horserad-
ish-peroxidase (HRP) conjugated; mouse anti-Myc HRP
conjugated antibody (1:5000) (Invitrogen); mouse anti-
V5 HRP conjugated antibody (1:5000) (Invitrogen); goat
anti-mouse-HRP antibody (1:1000) (Dako); goat anti-
rabbit HRP antibody (1:1000) (Dako); rabbit anti-goat
HRP (1:2000).
Immunofluorescence and microscopy
Transfected cells were harvested at 24 and 48 h post-
transfection by fixation in 3.7% formaldehyde-phosphate
buffered saline (PBS) (v/v) and permeabilized in 0.2% (v/
v) triton PBS for 5 min. Blocking of non-specific binding
of the secondary antibody was achieved routinely by
addition of 5% skim-milk powder (w/v) in Tris buffered
saline and 0.5% Tween (v/v) (TBS-T) before incubation
of the primary and secondary antibodies diluted in 1%
milk (w/v) in TBS-T. Removal of excess block and anti-
body was achieved with multiple washes of TBS-T.
Nuclei were counterstained with DAPI (Molecular
probes, Invitrogen).
For subcellular localization studies: Between 1000-
4000 transfected cells were counted for each construct
from at least three different transfection reactions using
standard fluorescence microscopy. The percent of trans-
fected cells with abnormal localization or aggregates was
determined as the number of cells containing abnormal
localization or aggregates divided by the total number of
ARX positive cells. Sub-cellular localization images were
captured by Leica TCS SP5 spectral confocal microscope
using a 100× Plan apochromat objective. Z-stacks were
taken at 0.25 μm intervals and maximal projections
were made for all cell images.
For mitosis studies: Between 1200 and 4000 cells were
analysed at 24, 48 and 72 h post-transfection for: (i) per-
centage of cells transfected; (ii) percentage of mitotic
cells in both transfected and un-transfected cells; and
(iii) and the phase of mitosis for each cell undergoing
division.
Yeast-2 hybrid screening
Plasmids encoding the ARX homeodomain (ARX-HD)
were fused to the GAL4 DNA binding domain and the
library protein were fused to GAL4-activation domain.
The MaV203 yeast strain was co-transformed with the
ARX-HD construct and human fetal brain cDNA library
(ProQuest, Invitrogen). Colonies were selected on media
lacking leucine, tryptophan and histidine and positive
clones were analysed for expression of three reporter
genes (HIS3, URA3 and LacZ) by measuring b-galactosi-
dase activity. Library inserts of positive clones that acti-
vated more than one reporter gene were amplified by
polymerase chain reaction and sequenced to determine
the identity of the library clone.
Co-immunoprecipitation
Cells transfected with Myc-ARX, both with and without
V5-IPO13 were harvested at 24 hrs post-transfection
and cell lysates prepared using lysis buffer (120 mM
NaCl, 50 mM Tris-HCl (pH 8.0), 0.5% NP-40 (v/v), 1×
protease inhibitor cocktail (Sigma, AZ, USA), 1 mM
Na3VO4, 1 mM NaF, 1 mM PMSF). Lysates were clari-
fied by centrifugation (15 min, 13,000 g at 4°C). Aliquots
of extracts were immunoprecipitated (IP) overnight at 4°
C. Protein-A sepharose was pre-treated with un-trans-
fected HEK293T cell lysate to ameliorate non-specific
binding of cell proteins. The IP reactions were incubated
with the pre-treated protein-A sepharose for 1 h at 4°C
before removal of non-specifically bound proteins with
four changes of high stringency wash buffer (500 mM
NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5%
NP-40 (v/v)) to ensure adequate removal of non-specific
binding of alanine tract containing ARX protein. Pro-
teins bound to the protein-A sepharose were eluted in
SDS loading buffer (62.5 mM Tris-HCl (pH 6.8), 2%
SDS (v/v), 10% glycerol (v/v), 5% b-Mercaptoethanol (v/
v), 0.001% bromophenol blue (w/v), heated to 65°C
before addition and incubated for 3 min). IP proteins
were subjected to SDS-PAGE and transferred to nitro-
cellulose membrane. Lysates from HEK293T cells pro-
ducing either Myc-ARX alone or V5-IPO13 alone were
used as controls.
In co-transfected cells; Myc-ARX protein was IP with
0.5 μg of anti-Myc antibody (Santa Cruz Biotech, CA,
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USA) or the reciprocal co-immunoprecipitation (Co-IP)
with 0.5 μg of rabbit anti-V5 antibody immunoprecipi-
tating V5-IPO13 protein. IP proteins were analysed for
the presence of Myc-ARX and V5-IPO13 by western
immunblotting. In cells transfected with ARX alone,
endogenous IPO13 was IP with 1 μg of goat anti-IPO13
and Co-IP of Myc-ARX protein was identified using
mouse anti-Myc HRP conjugated antibody.
To verify the interaction between Myc-ARX and
TUBA1A, HEK293T cells transfected with Myc-ARX
constructs were lysed and immunoprecipitated with
mouse anti-Myc antibody. IP proteins were analysed for
the presence of Myc-ARX and endogenous alpha-tubu-
lin by western immunoblotting.
Statistical analysis
All data are reported as mean ± standard error of mean,
determined from a minimum of three separate transfec-
tion reactions, with the number of cells counted indi-
cated in each figure legend. Differences in the
percentage of transfected cells with abnormal subcellular
localization were analysed by Kruskal-Wallis Test and
when significance was reached a one-tailed pair-wise
comparison was achieved using Wilcoxon-Mann-Whit-
ney U test. In the case of the mitosis data, differences in
the proportions of cells in various phases of mitosis at
increasing times post-transfection were compared by
two-way ANOVA, with mutations and time as factors. P
< 0.05 was considered significant.
Results
Novel mutations in ARX homeodomain
We have identified two novel point mutations in the
same residue of the NLS3 region of ARX homeodomain
in two unrelated families: (i) An apparently de novo and
novel single base substitution c.1136G>T in exon 4 of
ARX, resulting in the substitution of an arginine to a
leucine amino acid substitution at position 379 (R379L);
and (ii) A novel single base substitution c.1135C>A in
exon 4 of ARX was identified in the proband and three
female relatives [32], resulting in the substitution of an
arginine to a serine amino acid substitution at position
379 (R379S) (Figure 1). In the first case a clinical diag-
nosis of XLAG phenotype included mildly dysmorphic
features, ambiguous genitalia with a micropenis, fused
scrotum, cryptorchidism and a severe refractory seizure
disorder. Magnetic resonance imaging (MRI) identified
lissencephaly with agyria posteriorly transitioning in the
mid-parietal region to pachygyria anteriorly, agenesis of
the corpus callosum and a severe encephalopathy (Fig-
ure 1a-c). Other clinical findings include hypothalamic
dysfunction, hypophosphatasia and severe chronic diar-
rhoea with evidence of pancreatic insufficiency and
small bowel malabsorption. No developmental mile-
stones were attained and the disease was ultimately
lethal. The c.1136G>T mutation was not found in the
mother of the patient and her MRI brain scan showed a
normally formed corpus callosum (data not shown). In
the second case, the associated phenotype of carrier
females of the c.1135C>A mutation from the family
were reported [32]. We report here the clinical findings
of the male proband, who had a history of infantile
spasms and severe intellectual disability (Figure 1 Family
2, patient III-4). He was born after a pregnancy of 39
weeks by spontaneous delivery with a birth weight of
2600 g. In the first months eye contact was not ade-
quate. At the age of 6 months he experienced seizures
with tonic extension of the arms and turning of the eye
globes, which progressively increased in frequency and
were followed by apnoea. The electroencephalograph
showed a disorganized background pattern compatible
with hypsarrhythmia. On examination he was apathetic,
made no eye contact and showed insufficient sponta-
neous movements. His head growth progressively slowed
and at 6 years of age his occipitofrontal circumference
was below -2SD. He had no significant psychomotor
development and at 5 years of age had spastic tetrapar-
esis with truncal hypotonia. At 8 years of age he is
wheelchair bound, makes no eye contact, reacts to
touch and can chew and swallow food. He has recurrent
airway infections. His seizures are refractory to medical
treatment, notwithstanding the use of several antiepilep-
tic drug medications. Interestingly, this patient showed
no XLAG or brain malformation when examined by
MRI (data not shown). The patient had unilateral cryp-
torchidism. The presence of dry scaly skin prompted
testing for steroid sulphatase deficiency and the diagno-
sis was confirmed by genomic DNA analysis that
showed an STS gene deletion and leukocytes enzyme
assay that showed reduced activity (data not shown).
The borders of the STS deletion were fine mapped in
another family member with the same deletion by 250 K
SNP arrays and were comprised between SNP_A-
2122915 and SNP_A-1933813 on chromosome Xp22.
Missense mutations in NLS2 and NLS3 disrupt nuclear
localization of ARX
Transient transfection of full length Myc-tagged ARX-
Wt and mutants were conducted to examine changes in
subcellular localisation of the mutant proteins compared
to the ARX-Wt protein. We tested R332P, T333N,
R379L and R379S mutations (Figure 2A). We used con-
focal microscopy to analyse subcellular localisation,
highlighted for the R379L mutation (Figure 2B). Aggre-
gates are clearly distinguished in the peri-nuclear region
of the cytoplasm, with a large aggregate mass in the top
right quadrant. In addition to the cytoplasmic localisa-
tion, a series of aggregates in the nuclear space can be
identified. The percentage of transfected cells with aber-
rant sub-cellular localisation of ARX protein was
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assessed in at least 1000 transfected cells from a mini-
mum of three separate transfection experiments. For
counting purposes, transfected cells were categorised as
(1) normal localization; diffuse staining restricted to the
nucleus (Figure 2C, top panel) or (2) abnormal localiza-
tion, aggregates of mutant protein in either the nucleus
or in both the nucleus and cytoplasm (Figure 2C).
Expression of the Myc-tagged ARX-Wt protein was
detected in a non-homogenous pattern across the
nucleus with little or no expression detectable in the
cytoplasm. We observed this normal pattern of staining
in over 87% of cells transfected with ARX-Wt at 24 hrs
(Figure 2D) and 91% of cells at 48 h post-transfection
(data not shown). Transient over-expression leads to
aberrant localization of the ARX-Wt protein in approxi-
mately 13% of transfected cells (Figure 2D), generally in
the form of a single bright spot in the nucleus in addi-
tion to the normal diffuse staining (data not shown). In
contrast, ARX NLS mutant proteins were found within
the nucleus as either multiple, small aggregates, or
Figure 1 Pedigree of families with novel mutations in the ARX homeodomain. Open symbols represent normal individuals, filled symbols
represent affected individuals as per the key. Proband indicated with arrow. Individual generations are numbered with Roman numerals. MRI
findings in proband of family 1 (a) sagittal T1 MR sequence demonstrates lissencephaly P > A and marked lateral ventriculomegaly. Note
subependymal cysts (large arrow) abnormal periventricular white matter signal (small arrow) and abnormal basal ganglia signal clear arrow, (b)
sagittal T1 MR sequence of the midline demonstrates agenesis of the corpus callosum and (c) axial T2 MR sequence demonstrates colpocephaly
and lissencephaly with transition from posterior agyria (solid arrow) to anterior pachygyria (open arrow).
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longer continuous ‘ribbon like structures’ or larger
aggregates in which the DAPI stained nuclear material
had been excluded. The mutant protein was also found
in aggregates in the cytoplasm, often forming large
bodies to one side of the nucleus distorting the DAPI
stained nuclear material (Figure 2C). Routinely, cells
with abnormal localization of the mutant protein were a
mixture of cells with aggregates in the nucleus and no
detectable expression of ARX in the cytoplasm, in addi-
tion to cells with aggregates of mutant ARX in both the
nucleus and cytoplasm. No cells with ARX protein
exclusively in the cytoplasm were noted. The percen-
tages of transfected cells with abnormal ARX protein
localization were significantly elevated for all NLS muta-
tions tested compared to ARX-Wt transfected cells (Fig-
ure 2D). Mutations leading to severe clinical outcomes
resulted in the highest levels of cells with abnormal pro-
tein localization. Over-expression of R332P for 24 h
resulted in 72% of transfected cells in which the mutant
protein was incorrectly localized; an approx 5.5-fold
increase compared to the 13% of ARX-Wt transfected
cells. The T333N mutation, adjacent to the NLS2
region, mis-localized in 61% of transfected cells. Simi-
larly, the R379L mutation resulted in 60% of all trans-
fected cells with abnormal protein localization (Figure
2D). Unlike the other three mutations, the R379S mutai-
ton leads to a phenotype without malformation of the
brain. In cells expressing the R379S mutation the
increase in cells with abnormal localisation of mutant
protein was the lowest of all the mutations tested at
54% (Figure 2D). In contrast to the NLS mutations,
when another mutation the middle of the ARX homeo-
domain (P353L; XMESID phenotype) was expressed in
HEK293T cells there were no increased levels of cells
with mis-localized protein compared to ARX-Wt (Figure
2D). When a single construct containing two mutations
(R332P and R379L) was transfected into HEK293T cells
we found 90% of all of transfected cells displayed abnor-
mal localisation of the mutant protein (Figure 2D). This
increase was above the effect of either mutation alone
and indicates the NLS regions flanking the homeodo-
main are not redundant but likely act co-operatively.
Missense mutations in NLS2 and NLS3 do not abolish
ARX interaction with N-terminally truncated IPO13
In order to test if ARX with mutations in NLS2 or NLS3
were capable of binding to IPO13 in the cell environment
we co-transfected V5-tagged-IPO13 lacking the N-term-
inal RanGTPase binding site. This truncated V5-IPO13
protein can bind and transport the ARX cargo but is
unable to disassociate the cargo upon reaching the
RanGTP rich nuclear environment. We IP over-expressed
truncated V5-IPO13 by anti-V5 antibody (Figure 3A, top
box, second panel) and Myc-ARX by anti-Myc antibody
(Figure 3A, middle box, second panel) from whole cell
extracts, with no protein detected in parallel experiments
in which no IP antibody was added (Figure 3A, lane 1). In
cells expressing both Myc-ARX and V5-IPO13 we were
able to detect co-IP of Myc-ARX protein when immuno-
precipitating with anti-V5 antibody (Figure 3A, top box,
first panel) and in the reciprocal immunoprecipitation
with anti-Myc antibody we detected Co-IP of V5-IPO13
protein (Figure 3A, middle box, first panel). Regardless of
the antibody used for pull down we observed a stronger
Co-IP signal for all ARX mutant samples, including the
ARX protein containing the double NLS mutation com-
pared to the ARX-Wt protein. In agreement with the Co-
IP data, there was a shift in the truncated V5-IPO13 signal
from diffuse cytoplasmic localisation when transfected
alone (Figure 3B top panel) to complete overlap with the
nuclear expression of ARX-Wt protein (Figure 3B second
panel) and nuclear and cytoplasmic expression of NLS2
and NLS3 mutant ARX signal in co-transfected cells (Fig-
ure 3). These results were consistent across all of the
mutations tested, including the R332P-R379L mutant.
These results clearly indicate the mutant ARX proteins
were able to bind truncated V5-IPO13, even when there
were single amino acid substitutions in both NLS regions.
Endogenous IPO13 binds to ARX protein containing
missense mutations in NLS2 and NLS3
HEK293T cells express detectable levels of endogenous
IPO13 mRNA and protein. When we used an anti-IPO13
antibody the signal was localised as a diffuse punctate
staining across the cytoplasm (Figure 4A top panel). In
cells expressing mutant ARX, much of the endogenous
IPO13 signal was sequestered with the ARX protein, with
residual IPO13 signal in the cytoplasm (Figure 4A). This
co-localization was observed in all cells expressing mutant
ARX protein, including the protein with mutations in both
NLS2 and NLS3 (Figure 4A bottom panel). In contrast,
endogenous IPO13 protein did not co-localize with ARX-
Wt (Figure 4A second panel), likely due to efficient re-
cycling of IPO13 back to the cytoplasm after uncoupling
from ARX in the RanGTP rich environment of the
nucleus. We conclude that mutant ARX protein binding
to endogenous full length IPO13 localizes in the same
manner as if it were bound to the N-terminally truncated
V5-IPO13 that cannot physically uncouple from its cargo.
The interaction of endogenous IPO13 and mutant ARX
protein was confirmed by Co-IP of Myc-ARX NLS mutant
protein, but not the ARX-Wt protein from whole cell
extracts using an antibody against endogenous IPO13 (Fig-
ure 4B, top panel).
The binding of N-terminally truncated V5-IPO13 to ARX-
Wt increases the proportion of cells with abnormal ARX
protein localization
When Myc-ARX-Wt is co-expressed with V5-IPO13, we
measure an increased proportion of cells with abnormal
localization of the ARX-Wt protein compared to cells
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Figure 2 Missense mutations in nuclear localization sequence (NLS) regions of the Aristaless related homeobox (ARX) homeodomain
disrupt the normal nuclear subcellular localization in HEK293T cells. (A) Schematic of the human ARX protein. Known functional domains
are highlighted in the open reading frame: Octapeptide (OP) as horizontally hatched rectangle, NLS as three black rectangles, polyalanine tracts
(PA) as four white rectangles, acidic domain as vertically hatched rectangle, homeodomain crosshatched and Aristaless domain (OAR) hatched.
The sequences flanking the homeodomain are shown above the black rectangle, the locations indicated at either end, with the basic residues
that are part of the NLS-like motifs in bold. (B) Individual focal planes of cell transfected with Myc-R379L (NLS3) mutation construct show
aggregates of mutant ARX protein form both inside the nucleus and outside in the cytoplasm surrounding the nucleus. Panel on far left is at
the top of the cells (focal plane 2) with subsequent images an additional four focal planes further through the cell, maximal projection of all
images is shown on the far right. The aggregates often displace the nuclear material, shown by distortion and absence of the blue DAPI signal
in location of the aggregates. Scale bar = 10 μM. (C) Representative pictomicrographs of the localization of the Wt and mutant ARX protein 24
hrs post transfection. My~ ARX detected by anti-ARX Ab and Cy3 conjugated secondary antibody (left panel) merged with DAPI stained nuclear
material (right panel). Scale bar = 10 μM. (D) The percentage of transfected cells displaying abnormal localization as inclusions or aggregates in
the nucleus, with or without aggregates in the cytoplasm, was determined from between 1000 and 4000 transfected cells per construct, from at
least two separate transfection reactions, 24 h post-transfection. Full-length Myc-tagged constructs transfected are listed along the bottom of the
graph; ARX Wt (open bar), R332P (light grey bar), T333N (grey bar), P353L mutant (cross hatched bar), R379L and R379S (both dark grey bars)
and double mutant R332P-R379L (black bar). All groups comparison of the percentage of transfected cells with abnormal subcellular localization
of expressed ARX protein was achieved by parametric Kruskal-Wallis test. * P < 0.05 versus ARX-Wt, # versus ARX-NLS mutants with single aa
substitutions.
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expressing the ARX-Wt alone (Figure 5A). In cells
transfected with ARX alone we find 13% of cells with
abnormal ARX-Wt localisation (Figure 5B; in agreement
with previous result; Figure 2D), but when the cells are
co-expressing V5-IPO13 we note 60% of cells with
abnormal localization of ARX-Wt protein (Figure 5C).
In addition, these cells often had large or multiple
aggregates within the nucleus and in some cases in the
cytoplasm, reminiscent of the results for ARX-NLS
mutant proteins (data not shown). This data clearly
indicates that the binding of ARX-Wt protein to V5-
IPO13 contributes to aggregation and mis-localization
of the ARX.
Potential pathogenic mechanism of NLS mutations in ARX
In many cells with mutant ARX protein expression that
were undergoing mitosis we noted the mitotic spindles
were messy or even disrupted by aggregates of mutant
protein (Figure 6). This raised the question of whether
the formation of microtubules during cell division is
affected by sequestration of ARX.
Alpha Tubulin is a novel interacting protein partner of
ARX
Interactions of ARX with cytoskeletal and other proteins
were pursued using a GAL4-based yeast-2 hybrid screen.
We identified alpha-tubulin (TUBA1A; NM_006009.2)
and beta-tubulin (TUBB3; NM_006086.2) from a human
fetal brain cDNA library. The bait protein used in this
instance was the human ARX homeodomain (aa 303-
431) fused to the GAL4 DNA binding domain (GAL4-
DBD). This protein did not autoactivate the HIS3, lacZ
or URA3 reporter genes upon transformation of
MaV203 yeast (data not shown). Given the involvement
of mutations in TUBA1A in phenotypes with lissence-
phaly and other similar clinical findings to the severe
XLAG phenotype due to mutations in ARX we wanted
to investigate the novel interaction between ARX and
TUBA1A further. As there is a high level of similarity
between members of the alpha-tubulin family and we
predicted that ARX may interact not only with the brain
specific TUBA1A but also with other members of the
family. We confirmed this interaction in mammalian
cells by Co-IP. Overexpressed Myc-tagged ARX was
immunoprecipitated from whole cell extracts using a
monoclonal anti-Myc antibody. Endogenous alpha-tubu-
lin immunoprecipiated with Myc-ARX was detected by
rabbit anti-alpha-tubulin antibody (raised against a com-
mon immunogen; aa 417 to 441 of TUBA1A,
NP_00600.2) (Figure 7). When we tested the mutations
in the NLS regions of ARX we observed Co-IP of alpha-
tubulin for all samples, but not in parallel samples in
which no IP antibody was added (Figure 7). Our data
indicates that alpha-tubulin interacts with the homeodo-
main of ARX and this interaction is not abolished by
any of the NLS mutations tested. Despite the interaction
Figure 3 NLS mutant ARX co-immunoprecipitates and co-
localizes with N-terminally truncated IPO13 in mammalian
cells. (A) HEK293T cells transfected with Myc-ARX-Wt or NLS mutant
constructs and V5-IPO13 were lysed and protein
immunoprecipitated (IP) with antibodies against the V5 or Myc tags.
Samples were loaded onto 4%-12% SDS-PAGE gels and analysed for
the presence of co-IP proteins. Reciprocal Co-IPs was conducted on
replicate samples; IP with rabbit anti-V5 antibody (top panel) and
detection of Myc-ARX proteins bound to V5-IPO13 by
immunoblotting with mouse anti-Myc HRP conjugated antibody. All
samples transfected with V5-IPO13 showed a protein band of the
correct size upon blotting with anti-V5 horseradish-peroxidase (HRP)
conjugated antibody. IP with mouse anti-Myc antibody (middle
panel) and detection of V5-IPO13 protein bound to Myc-ARX by
immunblotting with mouse anti-V5 HRP conjugated antibody. All
samples transfected with Myc-ARX showed a protein band of the
correct size upon blotting with anti-Myc HRP conjugated antibody.
Specific IP of each over-expressed protein was achieved with no
band present in samples from cells transfected with both Myc-ARX
and V5-IPO13 but no IP antibody added (*). Cells transfected with
Myc-ARX alone or V5-IPO13 alone was used as negative controls.
V5-IPO13 (~88.6 kDa) and Myc-ARX (~62.2 kDa) are both present in
protein lysates (bottom panel). (B) Pictomicrographs showing V5-
IPO13 co-localises with ARX-Wt and mutant ARX protein (indicated
on left of panels) in both nuclear and cytoplasmic aggregates in
cells co-transfected with Myc-ARX and V5-IPO13 constructs for 24 h.
ARX detected by anti-ARX antibody and FITC conjugated secondary
antibody (left panel), V5-IPO13 detected by anti-IPO13 antibody and
Cy3 conjugated secondary antibody (middle panel) and merged
image including blue DAPI stained nuclear material (right panel).
Scale bar = 10 μM.
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of ARX and alpha-tubulin by yeast-2 hybrid studies and
Co-IP, in cells co-stained for Myc-ARX and alpha-tubu-
lin we did not see any apparent co-localization of the
two proteins. However, in mitotic cells expressing the
mutant ARX protein we noted the condensation of
DNA and the formation of mitotic spindles were often
localized around aggregates of the mutant protein (Fig-
ure 6).
Sequestration of mutant ARX and IPO13 may compromise
mitosis
The effects of the sequestration of mutant ARX with
IPO13 on mitosis and cell division were investigated at
24, 48 and 72 h post-transfection and compared with
ARX-Wt. Co-staining of ARX (transfected cells expres-
sing ARX protein), alpha-tublin (mitotic microtubules)
and nuclear material (DAPI) was conducted to assist
characterization of mitotic cells. At each time point cells
Figure 4 Endogenous IPO13 co-localizes and co-
immunoprecipitates with mutant ARX protein. (A)
Pictomicrographs showing sub-cellular localization of Wt and
mutant Myc-ARX detected by anti-ARX antibody and FITC
conjugated secondary antibody (left panel), endogenous IPO13
detected by anti-IPO13 antibody and Cy3 conjugated secondary
antibody (middle panel) and merged image including blue DAPI
stained nuclear material (right panel). Endogenous IPO13 co-
localises with Myc-ARX mutant protein, including the double
mutant R332P-R379L, in both nuclear and cytoplasmic aggregates,
but does not co-localize with the ARX-Wt protein (lane 1). (B)
HEK293T cells transfected with Myc-ARX-Wt or NLS mutant
constructs were lysed and protein IP with antibodies against
endogenous IPO13. Samples were loaded onto 4%-12% SDS-PAGE
gels and analysed for the presence of co-IP proteins. IP with Goat
anti-IPO13 antibody (top panel) and detection of Myc-ARX proteins
bound to IPO13 by immunoblotting with mouse anti-Myc HRP
conjugated antibody. All samples transfected with Myc-NLS mutant
ARX showed a protein band of the correct size upon blotting with
anti-Myc HRP conjugated antibody, with no band present in the
ARX-Wt lane. Endogenous IPO13 (~108 kDa) and Myc-ARX (~62.2
kDa) are both present in protein lysates (bottom box). Scale bar =
10 μM.
Figure 5 ARX-Wt protein is abnormally localized when co-
transfected with N-terminally truncated V5-IPO13. HEK293T cells
transfected with Myc-ARX-Wt and V5-IPO13 were assessed for
localization of the resulting ARX protein, either normal nuclear
localization (grey) or abnormal localization as inclusions or
aggregates in the nucleus, with or without aggregates in the
cytoplasm (black). (A) Combined count of cells transfected with ARX
with or without V5-IPO13, (B) cells with only ARX expression and (C)
cells with both ARX and V5-IPO13 expression.
Figure 6 Mitotic spindles disrupted by aggregates of NLS
mutant ARX protein. A representative pictomicrograph of a
HEK293T cell transfected with mutant Myc-ARX undergoing DNA
condensation stage of mitosis shows abnormal pattern of DNA
condensation (DAPI) microtubule formation (alpha-tubulin) around a
large aggregate of mutant ARX protein (Myc-ARX) with the
remaining Myc-ARX signal localized diffusely throughout the cell
interior. Scale bar = 10 μM.
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were analysed for: (i) percentage of cells transfected; (ii)
percentage of mitotic cells in both transfected and
untransfected cells; and (iii) and the phase of mitosis for
each cell undergoing division.
The percentage of cells expressing Myc-ARX were
higher in cells transfected with mutant ARX compared
to the ARX-Wt at all time points examined (Figure 8A).
This difference was ~1.3-fold at 24 h, increasing to 1.6-
to 2.2-fold by 48 h and between 2.3 (T333N) and 3.8
(R332P) fold by 72 h post-transfection. Although differ-
ences in the transfection efficiency may account for
some of the initial difference at 24 h, it appears that the
cells expressing mutant ARX protein persist in the
population longer than cells expressing the ARX-Wt
protein. The overall levels of mitosis (in both transfected
and un-transfected cells) were consistently between 4%-
5% of the total cell population, across all times and
treatment groups (data not shown). However, there was
a greater contribution to the mitotic pool in cells
expressing mutant ARX protein compared to the ARX-
Wt protein, increasingly prevalent with longer times
post-transfection (Figure 8B). For example, although
there were 1.3-fold more cells expressing R332P than
ARX-Wt at 24 h, there were 1.6-fold more mitotic cells
expressing the mutant protein compared to ARX-Wt
protein. This difference was doubled at the 48 h time
point, with 2.2-fold higher cells transfected but 4.4-fold
more mitotic cells in cells with R332P expression com-
pared to ARX-Wt. By 72 h post-transfection, although
there were 3.9-fold more cells expressing R332P com-
pared to ARX-Wt, the proportion undergoing mitosis
was 4.7-fold higher in favour of the ARX mutant.
In order to examine if there were any gross distur-
bances to the progression of the mitosis we scored each
mitotic cell as being either: (1) early phase: representa-
tive of DNA condensation during prophase and prome-
taphase; (2) middle phase - DNA lining up across the
mitotic spindle representative of metaphase; or (3) late
phase - representative of anaphase through to telophase
and cytokinesis. Each of these characteristic phases of
cell division was readily delineated using normal light
microscopy. Each mitotic cell was also scored as trans-
fected or un-transfected. The data for cells without ARX
expression undergoing mitosis for each time point was
pooled. Not surprisingly, these cells accounted for an
increasing proportion of mitotic cells across time points
Figure 7 Alpha tubulin co-immunoprecipitates with ARX in mammalian cells. HEK293T cells transfected with Myc-ARX full length protein
(FL-Wt), Myc-ARX-homeodomain (HD) or Myc-ARX-Aristaless (Arist) were lysed and proteins immunoprecipitated (IP) with mouse anti-Myc
antibody. Samples were loaded on 4%-12% SDS-PAGE gels and analysed for the presence of endogenous alpha tubulin precipitated with Myc-
ARX constructs by immunoblotting with rabbit anti-alpha tubulin antibody and goat anti-rabbit IgG conjugated to horseradish-peroxidase (HRP;
top panel). Specific IP of Myc-ARX was achieved with no band present in samples from cells transfected with each of the Myc-ARX constructs
but no IP antibody added (*). Myc-ARX full length (~62.2 kDa), Myc-ARX-HD (~19 kDa), Myc-ARX-Arist (~15 kDa) and endogenous alpha tubulin
(~50 kDa) are present in crude protein lysates (bottom panel). HEK293T cells transfected with Myc-ARX NLS mutations were subjected to IP as
above and alpha-tubulin was detected co-immunoprecipitating with all mutant ARX proteins (Left panel).
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post-transfection, from 71% to 76% and 89% at 24, 48
and 72 h, respectively. Within each time point, over half
of the mitotic cells without ARX expression were found
to exist in the early phase with the remaining cells split
between the middle and late phases (Figure 9A).
Although the proportion of these mitotic cells increased
with time post-transfection, the distribution across these
phases was consistent.
When mitotic cells expressing mutant ARX proteins
were analysed we saw an accumulation of cells under-
going mitosis compared to the cells expressing ARX-Wt
(Figure 9B). In particular, there was a significant
increase in the proportion of cells in the early phase of
mitosis at 24, 48 and 72 h post-transfection in cells
expressing the ARX NLS mutant proteins compared to
cells expressing ARX-Wt (with the exception of T333N
at 72 h). In cells expressing the ARX NLS mutations
there was also a significant increase in the proportion of
cells in the middle phase of mitosis at both 24 and 48 h
post-transfection compared to the ARX-Wt protein.
Interestingly, the percentages of cells in the late phase
of mitosis expressing NLS mutations were also
significantly higher than ARX-Wt at 48 h post-transfec-
tion (Figure 9B) but not at 72 h (data not shown). This
indicates that cells expressing the ARX NLS mutation
proteins are progressing through cell division at a slower
rate compared to the ARX-Wt protein.
Discussion
We have established that naturally occurring patient
mutations leading to non-synonymous changes of single,
specific residues of the NLS regions cause significant
disruption to nuclear localization of the mutant ARX
protein in vitro. These findings were consistent in all
NLS2 and NLS3 mutations tested, indicating the
Figure 8 Increased proportion of mitotic cells transfected with
nuclear localization sequence (NLS) mutant ARX. (A) The
percentage of HEK293T cells transfected and (B) the percentage of
mitotic cells transfected with Myc-ARX-Wt or NLS mutant constructs
for 24, 48 and 72 h was determined from between 1200 and 4000
cells per sample, from at least three separate transfection reactions.
Full-length Myc-tagged constructs transfected are indicated in the
legend ARX Wt (open), R332P (vertical light grey stripes), T333N
(grey), R379L (horizontal dark grey) and R379S (dark grey) with the
time post-transfection indicated on the X-axis.
Figure 9 Cells transfected with nuclear localization sequence
(NLS) mutant ARX accumulate in early mitosis. (A) The
percentage of un-transfected HEK293T cells undergoing various
phases of mitosis at 24, 48 and 72 h in culture (time indicated on
the X-axis) were determined from between 1200 and 4000 cells per
sample, from at least three separate transfection reactions. (B) The
percentage of mitotic cells at the DNA condensation stage (early
phase, light grey), mitotic spindle stage (middle phase, dark grey) or
undergoing anaphase/telophase/cytokinesis (late phase, black) are
shown for cells expressing Myc-ARX-Wt or NLS mutations 48 h post-
transfection. Full-length Myc-tagged ARX used in each group is
indicated on the X-axis. Differences in the percentage of cells
undergoing each phase of mitosis at different times post-
transfection were compared using a two-way ANOVA. P < 0.05
versus ARX-Wt for * early phase, + middle phase and # late phase.
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mechanism involved may be similar for missense muta-
tions in both NLS2 and NLS3 regions of the ARX
homeodomain. Consistent with the severity of clinical
outcomes, mutations leading to severe malformation
phenotypes had the highest percentages of cells with
abnormal mutant protein localization while the muta-
tion causing ISSX but not brain malformation gave the
smallest, but still significant, increase in cells with
abnormal protein localization compared to the ARX-Wt
protein. In contrast to the NLS mutations, another ARX
mutation in the middle of the homeodomain, but out-
side of the NLS regions, did not disrupt the nuclear
localization of the mutant protein with the subcellular
localization of the mutant protein the same as the ARX-
Wt protein.
The NLS regions flanking the ARX homeodomain are
predicted to be important in the bi-partite binding to
IPO13 [33,34]. We wanted to investigate if changing sin-
gle, specific residues of the NLS regions would diminish or
potentially abolish binding of the mutant NLS with IPO13.
The interaction of importins and cargo proteins are often
difficult to visualize or measure, as these interactions are
highly transient with efficient recycling of the importin
proteins back to the cytoplasm after delivery of the cargo
to the nucleus. In order to capture this interaction, N-
terminal truncated V5-IPO13 was engineered to enable
binding to cargo and transport across the nucleus coupled
with an inability to interact with RanGTP and dissociate
upon reaching the nucleus [33]. Both the Co-IP and co-
localization results indicate single amino acid substitutions
in either the NLS2 or NLS3 regions of the ARX homeodo-
main did not abolish binding of the mutant ARX protein
to N-terminally truncated V5-IPO13. Moreover, protein
containing both R332P and R379L mutations was still able
to bind to V5-IPO13.
Interestingly, binding of mutant ARX protein to endo-
genous IPO13 was indistinguishable from the binding to
the N-terminally truncated IPO13 lacking the RanGT-
Pase binding domain. The interaction of endogenous
IPO13 with mutant ARX protein implies that the bind-
ing of these two proteins not only occurs but that this
complex is either unable to correctly transport across
the nuclear pore or unable to discharge the ARX cargo
once inside the nucleus, or both. We contend that the
inability of mutant ARX to uncouple from endogenous
IPO13 contributes to the overall increase in cells with
abnormal localisation of ARX protein. In support of this
suggestion, co-transfection of ARX-Wt protein with the
N-terminally truncated IPO13 led to a marked increase
in the proportion of transfected cells with abnormal
localization compared to cells transfected with ARX-Wt
alone. Hence, disruption of normal nuclear delivery and
distribution of mutant ARX protein may be due to a
compromised ability of the mutant ARX-IPO13 complex
to uncouple in the presence of RanGTP. Inadequate
nuclear accumulation of a transcription factor due to
impaired interaction with importin-b has been suggested
as the pathogenic mechanism behind mutations in the
C-terminal NLS of the SRY gene leading to XY genotype
developing as females [38]. A similar scenario of inade-
quate accumulation and distribution of the mutant ARX
protein within the nucleus might ultimately mimic com-
plete absence of ARX and contribute to the catastrophic
phenotypic consequences routinely observed in patients
with these mutations. This prediction fits with the emer-
ging genotype-phenotype pattern for mutations in ARX.
In particular, naturally occurring mutations such as
insertions [5,7,9,12], deletions [5,28-31], nonsense
changes [30] and splice mutations [30] in ARX that
result in protein truncation and loss-of function of the
mature ARX protein invariably lead to severe pheno-
types, including XLAG.
Both arginine residues examined in this study, R332 in
NLS2 and R379 in NLS3 of ARX, are invariant in all 26
paired-type homeodomain proteins. Within this family
of proteins these two basic residues are frequent sites of
missense and nonsense mutations associated with a
range of diseases. A mutation in the homologous NLS2
residue has been reported for ALX4 (MIM 605420) [39]
and mutations in the homologous NLS3 residue have
been identified in CRX (MIM 602225) [40], OTX2
(MIM 600037) [41] and SHOX (MIM 312865) [42,43].
Mutations in both residues corresponding to the R332
and R379 of ARX have been identified in PAX3 (MIM
606597) [44,45], PAX6 (MIM 607108) [46,47], PITX2
(MIM 601542) [48-50] and PROP1 (MIM 601538)
[51-54]. A mutation in the conserved residue at position
50 of the paired-type homeodomain SHOX results in
the abolition of DNA binding [55]. This residue corre-
sponds to R379 of ARX. However, this residue is not
part of the NLS region of the SHOX protein. When a
residue within the NLS is mutated (R173C of SHOX)
this change does not affect the DNA binding but instead
disrupts the nuclear transport of SHOX. This may also
be the case with the mutations tested in our study.
There is no doubt that some of the missense mutations
in the ARX homeodomain are likely to be important in
either specificity of binding or in the actual binding to
DNA. For example, the P353L mutation did not disrupt
nuclear location of the resulting protein. Perhaps this
mutation leads to the severe XMESID phenotype due to
changes in binding to DNA targets. The recent identifi-
cation of a specific transcription factor-binding site for
Arx in a study ablating Arx in the sub-palluim of the
mouse brain [56] will provide an important tool to
investigate the potential mechanisms underlying the
pathogenesis of mutations in the ARX homeodomain in
the future.
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A recent examination of heterozygous females from
families with known mutations in ARX has highlighted
the fact that in some cases mutations that disrupt ARX
in females may have pathogenic consequences [32]. In
particular, a number of females with the T333N and
R379S mutations display mental retardation or learning
disabilities, although other female carriers of the same
mutation are phenotypically normal [30,32]. Our data
indicates that in addition to a predicted loss of normal
transcription factor activity of ARX, sequestration of
mutant ARX with IPO13 may lead to a disruption of
interactions with other protein partners, contributing to
the disease phenotype. An emerging feature of many
forms of lissencephaly and pachygyria is the potential
disruption of key elements of microtubule behaviour.
For example, one of the key genes mutated in lissence-
phaly is doublecortin (DCX). Mutations in DCX are
clustered in two tubulin binding domains and impair
the polymerization of microtubules and as such correct
neuronal migration [57]. Interestingly, DCX does not
bind to the tubulin heterodimer itself but acts to nucle-
ate the microtubule growth and to stabilize microtu-
bules. More recently, mutations in TUBA1A have been
reported to cause lissencephaly with a distinct clinical
presentation, ranging from perisylvian pachygyria in the
less severe form, to posteriorly predominant pachygyria
in the most severe form, in association with dysgenesis
of the anterior limb of the internal capsule and mild to
severe cerebellar hypoplasia [58]. A recurrent mutation
in TUBA1A compromises the efficiency of de novo
alpha/beta-tubulin heterodimer formation [59]. We have
shown that ARX interacts with TUBA1A by Co-IP, but
the two proteins do not appear to co-localize during
normal cell growth. However, in cells expressing mutant
ARX we observed a disruption of the mitotic spindle
structures and an accumulation of cells in the early
stages of mitosis. Hence, neurons, which normally
express ARX during the development of the sequestra-
tion of mutant ARX, might compromise the interaction
with TUBA1A, disrupt normal microtubule formation
and subsequently retard efficient cell division.
We cannot rule out the possibility that sequestration
of IPO13 in these cells may also contribute to pathogen-
esis. The dynamic cycling of Ran between the GTP and
GDP bound forms is exquisitely controlled by specific
regulators differentially localized within the cellular
environment [60]. The RanGAP, which accelerates GTP
hydrolysis, is cytoplasmic. The Ran guanine nucleotide
exchange factor, also known as RCC1 (regulator of
chromatin condensation 1), is located in the nucleus
bound to chromatin. Hence, the levels of RanGTP
increase in proximity to chromatin. Importin proteins
bind and inhibit spindle accessory factors (SAF) every-
where in the mitotic cytosol, except in the vicinity of
the chromosome. The high levels of RanGTP close to
the chromatin relieve the inhibition of SAFs by impor-
tins and subsequently allow local spindle assembly.
RanGTP binding to importin protein generates confor-
mation change in the Importin molecule that in turn
alters the binding site of the importin for the cargo pro-
teins [37]. Therefore, IPO13 trapped in complex with
mutant ARX may not be able to adequately bind SAFs
and as such compromise spindle assembly. Samples of
the cortex taken at autopsy from the patient with the
R379L mutation were stained with neurofilament immu-
noperoxidase and, interestingly, a paucity of neurons
was noted (D Coman, unpublished data). The authors
could not rule out the contribution of perinatal ischemia
to the histological findings. However, in light of our
findings, it is interesting to speculate that disruption of
the mitotic spindle due to sequestration of mutant ARX
with IPO13 retards cell division, potentially contributing
to a disruption in neuronal migration and correct lami-
nation patterns of the brain leading to lissencephaly and
associated clinical outcomes.
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